Allergy medicine for COPD with indoor allergies
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests if omalizumab, an allergy medicine, can help people with COPD who are allergic to common indoor allergens and have had recent flare-ups. It aims to see if reducing allergic reactions can improve COPD control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 40 years old.
- You must have a COPD diagnosis and be on daily inhaled therapy.
- You must have had a recent COPD flare-up (in the past year).
- You must be allergic to at least one common indoor allergen (cat, dog, mouse, cockroach, dust mites) and be exposed to it at home.
- You must have smoked at least 10 pack-years in your lifetime.
- You must not have asthma, other significant lung diseases, or certain infections like tuberculosis or parasitic infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if using air cleaners at home improves lung health in people with COPD. If you qualify, you may get an air cleaner for your home and be followed for 12 months.
This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This study tests a new biologic medicine, given as an injection, to see if it can reduce flare-ups in adults with COPD who have a certain type of inflammation. It may help people who still have frequent exacerbations despite using their current inhalers.
This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.
This study compares two allergy treatments for people with moderate asthma caused by dust mites. It tests whether a biologic injection (omalizumab) alone is as effective as combining it with allergy drops under the tongue (sublingual immunotherapy).
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.